Ondine Biomedical Inc. (AIM:OBI)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 53.51M -19.7% |
| Revenue (ttm) | 1.43M +29.1% |
| Net Income | -16.00M |
| EPS | -0.03 |
| Shares Out | 519.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 352 |
| Open | 10.25 |
| Previous Close | 10.30 |
| Day's Range | 10.00 - 10.50 |
| 52-Week Range | 7.50 - 15.50 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 2, 2026 |
About Ondine Biomedical
Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. ... [Read more]
Financial Performance
In 2025, Ondine Biomedical's revenue was 2.65 million, an increase of 29.14% compared to the previous year's 2.05 million. Losses were -29.52 million, 54.6% more than in 2024.
Financial numbers in CAD Financial StatementsNews
Ondine Biomedical Transcript: Study result
The LANTERN Phase 3 study met its primary endpoint, showing a 40.5% reduction in 30-day surgical site infections with nasal photodisinfection added to standard care, supported by robust Bayesian and frequentist analyses. The intervention demonstrated a strong safety profile and broad-spectrum efficacy, with rapid hospital payback and significant global market potential.
Ondine Biomedical Press release: Study result
Ondine Biomedical issued a press release on September 10, 2026, disclosing material business information to investors.
Ondine Biomedical Slides: Study result
Ondine Biomedical has posted slides in relation to its latest quarterly earnings report, which was published on September 10, 2026.
Ondine Biomedical Earnings Call Transcript: H2 2025
Revenue grew 29% to CAD 2.6M, driven by new hospital deployments and increased utilization, while R&D spend surged to support a pivotal phase III trial nearing readout. Manufacturing scale-up and commercial expansion are underway, with FDA submission targeted for the fall.
Ondine Biomedical Earnings release: H2 2025
Ondine Biomedical released its H2 2025 earnings on June 4, 2026, summarizing the period's financial results.
Ondine Biomedical Annual report: H2 2025
Ondine Biomedical has published its H2 2025 annual report on June 4, 2026.
Ondine Biomedical Slides: H2 2025
Ondine Biomedical has posted slides in relation to its H2 2025 quarterly earnings report, which was published on June 4, 2026.
Ondine Biomedical Earnings Call Transcript: H1 2025
Strong revenue and margin growth were achieved in H1 2025, with expanding adoption in Canada, the UK, and Europe. Strategic partnerships and a robust product pipeline support future growth, while recent funding secures operations through Q2 2026.
Ondine Biomedical Quarterly report: H1 2025
Ondine Biomedical has published its H1 2025 quarterly earnings report on September 26, 2025.
Ondine Biomedical Slides: H1 2025
Ondine Biomedical has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 26, 2025.
Ondine Biomedical's US $11M Fundraise Enables a Q4 2024 Start of Its Pivotal Phase 3 US Trial
VANCOUVER, British Columbia--(BUSINESS WIRE)--Ondine Biomedical announces that it is accelerating its US Phase 3 trial following its recent successful raise of Cdn $16 million (£9m, US $11m).